Triazole resistance surveillance in Aspergillus fumigatus.

Triazole resistance is an increasing concern in the opportunistic mold Aspergillus fumigatus. Resistance can develop through exposure to azole compounds during azole therapy or in the environment. Resistance mutations are commonly found in the Cyp51A-gene, although other known and unknown resistance mechanisms may be present. Surveillance studies show triazole resistance in six continents, although the presence of resistance remains unknown in many countries. In most countries, resistance mutations associated with the environment dominate, but it remains unclear if these resistance traits predominately migrate or arise locally. Patients with triazole-resistant aspergillus disease may fail to antifungal therapy, but only a limited number of cohort studies have been performed that show conflicting results. Treatment failure might be due to diagnostic delay or due to the limited number of alternative treatment options. The ISHAM/ECMM Aspergillus Resistance Surveillance working group was set up to facilitate surveillance studies and stimulate international collaborations. Important aims are to determine the resistance epidemiology in countries where this information is currently lacking, to gain more insight in the clinical implications of triazole resistance through a registry and to unify nomenclature through consensus definitions.

[1]  J. van Paassen,et al.  Influenza-Associated Aspergillosis in Critically Ill Patients. , 2017, American journal of respiratory and critical care medicine.

[2]  A. Mikos,et al.  Changes in In Vitro Susceptibility Patterns of Aspergillus to Triazoles and Correlation With Aspergillosis Outcome in a Tertiary Care Cancer Center, 1999–2015 , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  J. Meis,et al.  Intercountry Transfer of Triazole-Resistant Aspergillus fumigatus on Plant Bulbs , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  B. Zwaan,et al.  A Novel Environmental Azole Resistance Mutation in Aspergillus fumigatus and a Possible Role of Sexual Reproduction in Its Emergence , 2017, mBio.

[5]  P. Le Pape,et al.  Azole-resistant Aspergillus fumigatus harboring TR34/L98H, TR46/Y121F/T289A and TR53 mutations related to flower fields in Colombia , 2017, Scientific Reports.

[6]  A. Chowdhary,et al.  Clinical implications of globally emerging azole resistance in Aspergillus fumigatus , 2016, Philosophical Transactions of the Royal Society B: Biological Sciences.

[7]  J. Cornelissen,et al.  PCR-based detection of Aspergillus fumigatus Cyp51A mutations on bronchoalveolar lavage: a multicentre validation of the AsperGenius assay® in 201 patients with haematological disease suspected for invasive aspergillosis. , 2016, The Journal of antimicrobial chemotherapy.

[8]  B. Zwaan,et al.  In-host adaptation and acquired triazole resistance in Aspergillus fumigatus: a dilemma for clinical management. , 2016, The Lancet. Infectious diseases.

[9]  D. Denning,et al.  Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the infectious diseases society of America , 2016 .

[10]  W. Melchers,et al.  Azole resistance surveillance in Aspergillus fumigatus: beneficial or biased? , 2016, The Journal of antimicrobial chemotherapy.

[11]  E. Kuijper,et al.  Emerging aspergillosis by azole-resistant Aspergillus fumigatus at an intensive care unit in the Netherlands, 2010 to 2013. , 2016, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[12]  J. Meis,et al.  Azole-resistant Aspergillus fumigatus in Denmark: a laboratory-based study on resistance mechanisms and genotypes. , 2016, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[13]  W. Melchers,et al.  Voriconazole-Susceptible and Voriconazole-Resistant Aspergillus fumigatus Coinfection. , 2016, American journal of respiratory and critical care medicine.

[14]  T. Lagu,et al.  Association Between Initial Route of Fluoroquinolone Administration and Outcomes in Patients Hospitalized for Community-acquired Pneumonia. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  W. Melchers,et al.  Next-Generation Sequencing in the Mycology Lab , 2016, Current Fungal Infection Reports.

[16]  M. Cogliati,et al.  Azole Resistance in Aspergillus fumigatus Clinical Isolates from an Italian Culture Collection , 2015, Antimicrobial Agents and Chemotherapy.

[17]  H. Fan,et al.  First Detection of TR34 L98H and TR46 Y121F T289A Cyp51 Mutations in Aspergillus fumigatus Isolates in the United States , 2015, Journal of Clinical Microbiology.

[18]  J. Meis,et al.  High prevalence of azole resistance in Aspergillus fumigatus isolates from high-risk patients. , 2015, The Journal of antimicrobial chemotherapy.

[19]  W. Melchers,et al.  Genotype-phenotype complexity of the TR46/Y121F/T289A cyp51A azole resistance mechanism in Aspergillus fumigatus. , 2015, Fungal genetics and biology : FG & B.

[20]  B. Ener,et al.  First determination of azole resistance in Aspergillus fumigatus strains carrying the TR34/L98H mutations in Turkey. , 2015, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[21]  S. Seyedmousavi,et al.  International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus. , 2015, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[22]  P. Hauser,et al.  Prospective Multicenter International Surveillance of Azole Resistance in Aspergillus fumigatus , 2015, Emerging infectious diseases.

[23]  J. Boelens,et al.  Nationwide Surveillance of Azole Resistance in Aspergillus Diseases , 2015, Antimicrobial Agents and Chemotherapy.

[24]  A. Chowdhary,et al.  Prevalence and mechanism of triazole resistance in Aspergillus fumigatus in a referral chest hospital in Delhi, India and an update of the situation in Asia , 2015, Front. Microbiol..

[25]  J. Buer,et al.  Emergence of azole-resistant invasive aspergillosis in HSCT recipients in Germany. , 2015, The Journal of antimicrobial chemotherapy.

[26]  S. Seyedmousavi,et al.  Pharmacodynamics of Isavuconazole in an Aspergillus fumigatus Mouse Infection Model , 2015, Antimicrobial Agents and Chemotherapy.

[27]  J. Meis,et al.  Concomitant occurrence of itraconazole-resistant and -susceptible strains of Aspergillus fumigatus in routine cultures. , 2015, The Journal of antimicrobial chemotherapy.

[28]  J. Rello,et al.  Epidemiology of invasive aspergillosis in critically ill patients: clinical presentation, underlying conditions, and outcomes , 2015, Critical Care.

[29]  G. Simons,et al.  Validation of a New Aspergillus Real-Time PCR Assay for Direct Detection of Aspergillus and Azole Resistance of Aspergillus fumigatus on Bronchoalveolar Lavage Fluid , 2015, Journal of Clinical Microbiology.

[30]  M. Webber,et al.  Molecular mechanisms of antibiotic resistance , 2014, Nature Reviews Microbiology.

[31]  D. Denning,et al.  The clinical spectrum of pulmonary aspergillosis , 2014, Thorax.

[32]  A. Chowdhary,et al.  Exploring azole antifungal drug resistance in Aspergillus fumigatus with special reference to resistance mechanisms. , 2014, Future microbiology.

[33]  A. Chowdhary,et al.  Azole-resistant Aspergillus fumigatus with the environmental TR46/Y121F/T289A mutation in India. , 2014, The Journal of antimicrobial chemotherapy.

[34]  D. Andes,et al.  Isavuconazole (BAL4815) Pharmacodynamic Target Determination in an In Vivo Murine Model of Invasive Pulmonary Aspergillosis against Wild-Type and cyp51 Mutant Isolates of Aspergillus fumigatus , 2013, Antimicrobial Agents and Chemotherapy.

[35]  F. V. van Tiel,et al.  Aspergillosis due to voriconazole highly resistant Aspergillus fumigatus and recovery of genetically related resistant isolates from domiciles. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[36]  D. Denning,et al.  The cdr1B efflux transporter is associated with non-cyp51a-mediated itraconazole resistance in Aspergillus fumigatus. , 2013, The Journal of antimicrobial chemotherapy.

[37]  M. Christner,et al.  cyp51A-Based Mechanisms of Aspergillus fumigatus Azole Drug Resistance Present in Clinical Samples from Germany , 2013, Antimicrobial Agents and Chemotherapy.

[38]  S. Seyedmousavi,et al.  Azole-Resistant Aspergillus fumigatus, Iran , 2013, Emerging infectious diseases.

[39]  P. Escribano,et al.  Is Azole Resistance in Aspergillus fumigatus a Problem in Spain? , 2013, Antimicrobial Agents and Chemotherapy.

[40]  D. Cole,et al.  Global burden of allergic bronchopulmonary aspergillosis with asthma and its complication chronic pulmonary aspergillosis in adults. , 2013, Medical mycology.

[41]  D. Denning,et al.  High-level expression of cyp51B in azole-resistant clinical Aspergillus fumigatus isolates. , 2013, The Journal of antimicrobial chemotherapy.

[42]  A. Chowdhary,et al.  Clonal Expansion and Emergence of Environmental Multiple-Triazole-Resistant Aspergillus fumigatus Strains Carrying the TR34/L98H Mutations in the cyp51A Gene in India , 2012, PloS one.

[43]  M. Huynen,et al.  Discovery of a hapE Mutation That Causes Azole Resistance in Aspergillus fumigatus through Whole Genome Sequencing and Sexual Crossing , 2012, PloS one.

[44]  J. Cutright,et al.  In vitro-in vivo correlation of voriconazole resistance due to G448S mutation (cyp51A gene) in Aspergillus fumigatus. , 2012, Diagnostic microbiology and infectious disease.

[45]  P. Jorens,et al.  Invasive pulmonary aspergillosis is a frequent complication of critically ill H1N1 patients: a retrospective study , 2012, Intensive Care Medicine.

[46]  D. Cole,et al.  Global burden of chronic pulmonary aspergillosis complicating sarcoidosis , 2012, European Respiratory Journal.

[47]  W. Melchers,et al.  Triazole Fungicides Can Induce Cross-Resistance to Medical Triazoles in Aspergillus fumigatus , 2012, PloS one.

[48]  D. Cole,et al.  Global burden of chronic pulmonary aspergillosis as a sequel to pulmonary tuberculosis. , 2011, Bulletin of the World Health Organization.

[49]  W. Melchers,et al.  The structure-function relationship of the Aspergillus fumigatuscyp51A L98H conversion by site-directed mutagenesis: the mechanism of L98H azole resistance. , 2011, Fungal genetics and biology : FG & B.

[50]  T. Nishino,et al.  Antifungal Susceptibilities of Aspergillus fumigatus Clinical Isolates Obtained in Nagasaki, Japan , 2011, Antimicrobial Agents and Chemotherapy.

[51]  E. Kuijper,et al.  Rapid Induction of Multiple Resistance Mechanisms in Aspergillus fumigatus during Azole Therapy: a Case Study and Review of the Literature , 2011, Antimicrobial Agents and Chemotherapy.

[52]  R. A. Cramer,et al.  SREBP-Dependent Triazole Susceptibility in Aspergillus fumigatus Is Mediated through Direct Transcriptional Regulation of erg11A (cyp51A) , 2011, Antimicrobial Agents and Chemotherapy.

[53]  F. V. van Tiel,et al.  Clinical Implications of Azole Resistance in Aspergillus fumigatus, the Netherlands, 2007–2009 , 2011, Emerging infectious diseases.

[54]  S. Lockhart,et al.  Azole Resistance in Aspergillus fumigatus Isolates from the ARTEMIS Global Surveillance Study Is Primarily Due to the TR/L98H Mutation in the cyp51A Gene , 2011, Antimicrobial Agents and Chemotherapy.

[55]  A. Warris,et al.  Aspergillus species intrinsically resistant to antifungal agents. , 2011, Medical mycology.

[56]  E. Petinaki,et al.  Polyphasic Identification and Susceptibility to Seven Antifungals of 102 Aspergillus Isolates Recovered from Immunocompromised Hosts in Greece , 2011, Antimicrobial Agents and Chemotherapy.

[57]  R. Rajendran,et al.  Azole Resistance of Aspergillus fumigatus Biofilms Is Partly Associated with Efflux Pump Activity , 2011, Antimicrobial Agents and Chemotherapy.

[58]  D. Denning,et al.  Azole antifungal resistance in Aspergillus fumigatus: 2008 and 2009. , 2010, The Journal of antimicrobial chemotherapy.

[59]  W. Melchers,et al.  Impact of cyp51A Mutations on the Pharmacokinetic and Pharmacodynamic Properties of Voriconazole in a Murine Model of Disseminated Aspergillosis , 2010, Antimicrobial Agents and Chemotherapy.

[60]  D. Kelly,et al.  Expression, Purification, and Characterization of Aspergillus fumigatus Sterol 14-α Demethylase (CYP51) Isoenzymes A and B , 2010, Antimicrobial Agents and Chemotherapy.

[61]  Thomas J Walsh,et al.  Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[62]  E. Anaissie,et al.  Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[63]  W. Melchers,et al.  Azole Resistance Profile of Amino Acid Changes in Aspergillus fumigatus CYP51A Based on Protein Homology Modeling , 2010, Antimicrobial Agents and Chemotherapy.

[64]  W. Melchers,et al.  Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use? , 2009, The Lancet. Infectious diseases.

[65]  D. Denning,et al.  zole-resistance in Aspergillus: Proposed nomenclature and breakpoints , 2009 .

[66]  J. Baddley,et al.  Patterns of Susceptibility of Aspergillus Isolates Recovered from Patients Enrolled in the Transplant-Associated Infection Surveillance Network , 2009, Journal of Clinical Microbiology.

[67]  I. T. Ten Berge,et al.  Multiple-azole-resistant Aspergillus fumigatus osteomyelitis in a patient with chronic granulomatous disease successfully treated with long-term oral posaconazole and surgery. , 2009, Medical mycology.

[68]  D. Denning,et al.  Frequency and Evolution of Azole Resistance in Aspergillus fumigatus Associated with Treatment Failure , 2009, Emerging infectious diseases.

[69]  W. Melchers,et al.  Possible Environmental Origin of Resistance of Aspergillus fumigatus to Medical Triazoles , 2009, Applied and Environmental Microbiology.

[70]  E. Anaissie,et al.  Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[71]  W. Melchers,et al.  Academic Editor: Chris Kibbler, Royal Free Hospital London, United Kingdom , 2007 .

[72]  Martin Bard,et al.  A Sterol-Regulatory Element Binding Protein Is Required for Cell Polarity, Hypoxia Adaptation, Azole Drug Resistance, and Virulence in Aspergillus fumigatus , 2008, PLoS pathogens.

[73]  W. Melchers,et al.  Efficacy of Posaconazole against Three Clinical Aspergillus fumigatus Isolates with Mutations in the cyp51A Gene , 2008, Antimicrobial Agents and Chemotherapy.

[74]  W. Melchers,et al.  Multiple-triazole-resistant aspergillosis. , 2007, The New England journal of medicine.

[75]  W. Melchers,et al.  A New Aspergillus fumigatus Resistance Mechanism Conferring In Vitro Cross-Resistance to Azole Antifungals Involves a Combination of cyp51A Alterations , 2007, Antimicrobial Agents and Chemotherapy.

[76]  D. Denning,et al.  Multi-azole resistance in Aspergillus fumigatus. , 2006, International journal of antimicrobial agents.

[77]  E. Mellado,et al.  Substitutions at Methionine 220 in the 14α-Sterol Demethylase (Cyp51A) of Aspergillus fumigatus Are Responsible for Resistance In Vitro to Azole Antifungal Drugs , 2004, Antimicrobial Agents and Chemotherapy.

[78]  Michael Light,et al.  Allergic bronchopulmonary aspergillosis in cystic fibrosis--state of the art: Cystic Fibrosis Foundation Consensus Conference. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[79]  E. Mellado,et al.  A Point Mutation in the 14α-Sterol Demethylase Gene cyp51A Contributes to Itraconazole Resistance in Aspergillus fumigatus , 2003, Antimicrobial Agents and Chemotherapy.

[80]  D. Stevens,et al.  Antifungal drug resistance. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[81]  Richard Sylvester,et al.  Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. , 2002, The New England journal of medicine.

[82]  E. Anaissie,et al.  Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. , 2002, The New England journal of medicine.

[83]  William R. Kirkpatrick,et al.  Invasive Aspergillosis Disease Spectrum, Treatment Practices, and Outcomes , 2000, Medicine.

[84]  S. Kelly,et al.  Itraconazole resistance in Aspergillus fumigatus , 1997, Antimicrobial agents and chemotherapy.

[85]  A. Brillowska-Dąbrowska,et al.  Detection of Polish clinical Aspergillus fumigatus isolates resistant to triazoles. , 2018, Medical mycology.

[86]  P. Le Pape,et al.  Home Environment as a Source of Life-Threatening Azole-Resistant Aspergillus fumigatus in Immunocompromised Patients. , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[87]  Z. Wan,et al.  Mutations in the cyp51A gene and susceptibility to itraconazole in Aspergillus fumigatus serially isolated from a patient with lung aspergilloma. , 2005, The Journal of antimicrobial chemotherapy.

[88]  A. Wilmer,et al.  Invasive aspergillosis in critically ill patients without malignancy. , 2004, American journal of respiratory and critical care medicine.